HBC Stock Overview
Operates as a consumer and pet health ingredient supplier and incubator in Norway, the United Kingdom, France, Belgium, Europe, Japan, Asia, and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Hofseth BioCare ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 1.30 |
| 52 Week High | NOK 2.82 |
| 52 Week Low | NOK 1.20 |
| Beta | 0.34 |
| 11 Month Change | -18.75% |
| 3 Month Change | -39.25% |
| 1 Year Change | -53.24% |
| 33 Year Change | -79.10% |
| 5 Year Change | -87.68% |
| Change since IPO | -74.00% |
Recent News & Updates
Recent updates
Here's Why Hofseth BioCare (OB:HBC) Can Afford Some Debt
Apr 01
We Think Hofseth BioCare (OB:HBC) Has A Fair Chunk Of Debt
Dec 22Health Check: How Prudently Does Hofseth BioCare (OB:HBC) Use Debt?
Apr 28Hofseth BioCare (OB:HBC) Is Carrying A Fair Bit Of Debt
Oct 16Is Hofseth BioCare (OB:HBC) Using Debt Sensibly?
Feb 24How Much Of Hofseth BioCare ASA (OB:HBC) Do Insiders Own?
Jan 28Are Insiders Buying Hofseth BioCare ASA (OB:HBC) Stock?
Dec 25
Hofseth BioCare (OB:HBC) Shareholders Have Enjoyed A Whopping 339% Share Price Gain
Nov 20Shareholder Returns
| HBC | NO Biotechs | NO Market | |
|---|---|---|---|
| 7D | -6.5% | 8.9% | 3.1% |
| 1Y | -53.2% | -69.4% | 3.9% |
Return vs Industry: HBC exceeded the Norwegian Biotechs industry which returned -69.4% over the past year.
Return vs Market: HBC underperformed the Norwegian Market which returned 3.9% over the past year.
Price Volatility
| HBC volatility | |
|---|---|
| HBC Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in NO Market | 10.6% |
| 10% least volatile stocks in NO Market | 2.7% |
Stable Share Price: HBC's share price has been volatile over the past 3 months compared to the Norwegian market.
Volatility Over Time: HBC's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Norwegian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 70 | Jon Odegard | www.hofsethbiocare.com |
Hofseth BioCare ASA operates as a consumer and pet health ingredient supplier and incubator in Norway, the United Kingdom, France, Belgium, Europe, Japan, Asia, and the United States. The company’s products include OmeGo, a salmon oil, which offers the full spectrum of fatty acids and omegas found naturally in fresh whole salmon; ProGo, a bioactive peptide for VMS, metabolism, and active nutrition needs; CalGo, an absorbable complex mineral for bone and joint health; CollaGo; and PetGo, a non-soluble protein. The company was incorporated in 2000 and is headquartered in Ålesund, Norway.
Hofseth BioCare ASA Fundamentals Summary
| HBC fundamental statistics | |
|---|---|
| Market cap | NOK 550.85m |
| Earnings (TTM) | -NOK 133.48m |
| Revenue (TTM) | NOK 248.08m |
2.2x
P/S Ratio-4.0x
P/E RatioIs HBC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HBC income statement (TTM) | |
|---|---|
| Revenue | NOK 248.08m |
| Cost of Revenue | NOK 187.72m |
| Gross Profit | NOK 60.36m |
| Other Expenses | NOK 193.83m |
| Earnings | -NOK 133.48m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
| Earnings per share (EPS) | -0.32 |
| Gross Margin | 24.33% |
| Net Profit Margin | -53.80% |
| Debt/Equity Ratio | 189.8% |
How did HBC perform over the long term?
See historical performance and comparison